Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2024-06-03 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Report Publication Announcement Classification · 1% confidence The document is extremely short (1840 characters) and explicitly states that a report is attached: "Attached hereto is a report on*6k* *6k03062024_isa.pdf*". The reference to '6k' suggests an SEC Form 6-K, which is typically used by foreign private issuers for material events. Since this document is merely announcing the publication of the actual 6-K filing (which is attached as a PDF), it fits the definition of a Report Publication Announcement (RPA) according to Rule 2: Differentiating between a report itself and an announcement of a report. It is not the full 10-K, IR, or ER, but the announcement of the filing.
2024-06-03 English
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934" for the month of May 2024. Form 6-K is used by foreign private issuers to report material information not required to be reported in their home country or to shareholders. This filing details a significant capital raising event (a registered direct offering involving ordinary shares, pre-funded warrants, and investor warrants) and includes the executed Securities Purchase Agreement as an exhibit. While it contains financial transaction details, it is not the comprehensive Annual Report (10-K), an Interim Report (IR), or a simple Earnings Release (ER). It is a specific, periodic regulatory filing for material events by a foreign issuer. Since there is no specific code for Form 6-K, and it is a mandatory regulatory filing reporting material information, the most appropriate general category for non-standard SEC filings that don't fit other specific definitions (like 10-K, DEF 14A, etc.) is Regulatory Filings (RNS). However, given the nature of the content (a detailed report on a financing transaction, which is a material event), and the fact that Form 6-K is a standard SEC form for foreign issuers, it often falls under the general regulatory disclosure category. Since RNS is defined as "General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories," and Form 6-K is a specific, recurring report type, RNS is the best fit among the provided options for a non-US periodic/event-driven filing that isn't a full annual/interim report.
2024-05-30 English
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Report Publication Announcement Classification · 1% confidence The document is extremely short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k29052024_isa.pdf*". This structure—a brief announcement pointing to an attached or linked report (in this case, a Form 6-K filing, which is a general SEC filing for foreign private issuers)—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is announcing the publication of a report rather than being the full report itself. Since RPA is a specific category for such announcements, it is preferred over the general 'RNS' fallback.
2024-05-30 English
Prospectus Supplement
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "Prospectus Supplement to Prospectus dated May 5, 2022" and details an offering of ordinary shares, warrants, and pre-funded warrants by Enlivex Therapeutics Ltd. It discusses the terms of the offering, the placement agent's role, and includes a detailed Table of Contents for both the supplement and the accompanying prospectus. This structure is characteristic of a registration statement filed with the SEC related to a securities offering, which falls under the category of Capital/Financing Update (CAP) as it describes the terms and mechanics of raising capital through the sale of securities. It is not a standard periodic report (10-K, IR) or a simple announcement (RPA, RNS).
2024-05-30 English
Prospectus Supplement
Report Publication Announcement Classification · 1% confidence The document is a filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Enlivex prosupp* *Prospectus_Supplement29052024_isa.pdf*'. This structure—a brief regulatory notification announcing the publication of an attached document (a Prospectus Supplement)—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself, but the announcement of its release. The document length is short (1859 chars), supporting the RPA classification over a comprehensive report like 10-K or IR.
2024-05-30 English
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Capital/Financing Update Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is a report filed by Foreign Private Issuers to report material information that is made public in their home country or required to be filed with a foreign securities exchange. The content details a 'registered direct offering' of shares and warrants, which is a financing/capital raising activity. While the core event is a capital raise (CAP), the document itself is a mandatory SEC filing (Form 6-K) used to report material events. Since 'CAP' is for updates on fundraising and '10-K' is for annual reports, and there is no specific code for Form 6-K, we must determine the best fit. Form 6-K filings often contain material non-public information disclosures. Given the subject matter is a definitive agreement for the issuance and sale of shares and warrants, this strongly aligns with 'Capital/Financing Update' (CAP). However, Form 6-K is a general reporting mechanism. In the provided schema, there is no direct code for Form 6-K. The closest functional match for an announcement detailing the terms of a share issuance/financing is 'CAP' (Capital/Financing Update). If the document were purely an announcement of the *publication* of this news, RPA might apply, but this is the actual filing containing the details. Since the document details the terms of a financing, CAP is the most appropriate functional classification, even though the regulatory form is 6-K.
2024-05-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.